These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Netherton SJ; Maurice DH Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573 [TBL] [Abstract][Full Text] [Related]
36. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Castro A; Jerez MJ; Gil C; Martinez A Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991 [TBL] [Abstract][Full Text] [Related]
37. Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides. Lomas O; Zaccolo M Physiology (Bethesda); 2014 Mar; 29(2):141-9. PubMed ID: 24583770 [TBL] [Abstract][Full Text] [Related]
38. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Mehats C; Andersen CB; Filopanti M; Jin SL; Conti M Trends Endocrinol Metab; 2002; 13(1):29-35. PubMed ID: 11750860 [TBL] [Abstract][Full Text] [Related]
39. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Lugnier C Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838 [TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Andersson KE; Uckert S; Stief C; Hedlund P Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]